DexCom Stock Price, News & Analysis (NASDAQ:DXCM)

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

15 brokers have issued 12 month price targets for DexCom's shares. Their DXCM share price targets range from $100.00 to $160.00. On average, they predict the company's stock price to reach $132.33 in the next year. This suggests a possible upside of 13.1% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $113.24 at the start of the year. Since then, DXCM stock has increased by 3.3% and is now trading at $116.97.
View the best growth stocks for 2023 here.

DexCom saw a decline in short interest in November. As of November 15th, there was short interest totaling 17,750,000 shares, a decline of 15.7% from the October 31st total of 21,060,000 shares. Based on an average daily trading volume, of 5,150,000 shares, the short-interest ratio is currently 3.4 days.
View DexCom's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our DXCM earnings forecast.

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, October, 26th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.16. The medical device company earned $975 million during the quarter, compared to analyst estimates of $939.64 million. DexCom had a net margin of 11.08% and a trailing twelve-month return on equity of 25.05%. DexCom's quarterly revenue was up 26.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 EPS.
Read the conference call transcript.

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS).

DexCom's stock split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom updated its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.32%), Sands Capital Management LLC (3.54%), Blair William & Co. IL (1.17%), Jennison Associates LLC (1.11%), Northern Trust Corp (1.01%) and Clearbridge Investments LLC (0.84%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.